IDH2 and acute myeloid leukemia: These findings may have a clinical impact according to the favorable results from studies evaluating ivosidenib and enasidenib (anti-IDH1 and IDH2, respectively) in patients with relapsed/refractory IDH-mutated AML [140,141], as well as high response rate of TP53-mutated AML to 10-day decitabine [142].